FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2809920244> ?p ?o ?g. }

• W2809920244 endingPage "576" @default.
• W2809920244 startingPage "567" @default.
• W2809920244 abstract "Plaque psoriasis affects approximately 2% to 3% of the global population, with psoriatic arthritis observed in approximately 20% to 30% of these individuals. Upon advances in research pathophysiology and treatment over the past decade, biologic therapies have been used more to treat moderate to severe psoriasis. In Canada, reimbursement bodies have defined prior authorization criteria to determine patient eligibility for funding of biologic treatments in moderate to severe plaque psoriasis. Generally, patients will have been treated with conventional therapies such as topical steroids, phototherapy, or systemic treatments such as methotrexate and cyclosporine before starting a biologic therapy. In difficult cases or severe flares in otherwise controlled disease, practitioners may augment the regimen with one or more conventional treatments. The objective of this observational report was to identify treatment pathways for psoriasis and psoriatic arthritis patients in Canada by examining initial biologic treatment and subsequent treatment optimization patterns for informed reimbursement discussions and decisions. A retrospective chart review was conducted at Newlab Clinical Research using medical records of patients who received at least 1 of 4 biologic agents approved at that time of the survey in Canada for the treatment of plaque psoriasis (adalimumab, etanercept, infliximab, ustekinumab). The study population consisted of patients who had moderate to severe plaque psoriasis, diagnosed by a dermatologist, for at least 6 months before the study index date and who attended Newlab Clinical Research between 2008 and 2013. All current and previous agents prescribed for the treatment of psoriasis were captured. A total of 248 patients with psoriasis treated with biologics were identified, of whom 27 (10.9%) were also diagnosed with psoriatic arthritis. Prior to initiating treatment with a biologic, most patients (72.1%) were treated with (or contraindicated to) methotrexate/cyclosporine. Treatment was supplemented with topical agents (70.6%) and/or followed by a course of ultraviolet light phototherapy (51.6%). Only 2.4% of patients were treated with a biologic first. Of 248 patients treated with biologics, almost half (47.6%) needed add-on therapy, whereas 16.5% of patients had an increase in dose or dosing interval. Furthermore, 14.1% of patients added a topical agent, 10.5% a topical steroid, or 6.5% a course of phototherapy while continuing biologic therapies. Finally, 30.4% of patients switched to another biologic treatment. Adalimumab was the most common agent used as a second-line agent (37.2%), and patients who started on adalimumab mainly switched to ustekinumab as a second-line agent (73.9%). Infliximab was the agent least often used as second-line therapy." @default.
• W2809920244 created "2018-07-10" @default.
• W2809920244 creator A5023510471 @default.
• W2809920244 creator A5040311529 @default.
• W2809920244 creator A5057965284 @default.
• W2809920244 creator A5060441791 @default.
• W2809920244 creator A5080688191 @default.
• W2809920244 creator A5090050746 @default.
• W2809920244 date "2018-06-28" @default.
• W2809920244 modified "2023-10-07" @default.
• W2809920244 title "Biologic Therapy Utilization in Patients With Moderate to Severe Psoriasis and Psoriatic Arthritis: An Observational Summary of Biologic Therapy Use in a Clinical Setting" @default.
• W2809920244 cites W1964975614 @default.
• W2809920244 cites W1976459566 @default.
• W2809920244 cites W1977036374 @default.
• W2809920244 cites W1989815163 @default.
• W2809920244 cites W2005428052 @default.
• W2809920244 cites W2011785288 @default.
• W2809920244 cites W2055018575 @default.
• W2809920244 cites W2056329160 @default.
• W2809920244 cites W2061103881 @default.
• W2809920244 cites W2064104912 @default.
• W2809920244 cites W2067802903 @default.
• W2809920244 cites W2085498159 @default.
• W2809920244 cites W2093116261 @default.
• W2809920244 cites W2101518880 @default.
• W2809920244 cites W2107730744 @default.
• W2809920244 cites W2113369166 @default.
• W2809920244 cites W2138763209 @default.
• W2809920244 cites W2166811019 @default.
• W2809920244 cites W2249030853 @default.
• W2809920244 cites W4249483860 @default.
• W2809920244 doi "https://doi.org/10.1177/1203475418786712" @default.
• W2809920244 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29952225" @default.
• W2809920244 hasPublicationYear "2018" @default.
• W2809920244 type Work @default.
• W2809920244 sameAs 2809920244 @default.
• W2809920244 citedByCount "7" @default.
• W2809920244 countsByYear W28099202442019 @default.
• W2809920244 countsByYear W28099202442020 @default.
• W2809920244 countsByYear W28099202442021 @default.
• W2809920244 countsByYear W28099202442022 @default.
• W2809920244 crossrefType "journal-article" @default.
• W2809920244 hasAuthorship W2809920244A5023510471 @default.
• W2809920244 hasAuthorship W2809920244A5040311529 @default.
• W2809920244 hasAuthorship W2809920244A5057965284 @default.
• W2809920244 hasAuthorship W2809920244A5060441791 @default.
• W2809920244 hasAuthorship W2809920244A5080688191 @default.
• W2809920244 hasAuthorship W2809920244A5090050746 @default.
• W2809920244 hasConcept C126322002 @default.
• W2809920244 hasConcept C16005928 @default.
• W2809920244 hasConcept C23131810 @default.
• W2809920244 hasConcept C2776260265 @default.
• W2809920244 hasConcept C2777138892 @default.
• W2809920244 hasConcept C2777226972 @default.
• W2809920244 hasConcept C2777575956 @default.
• W2809920244 hasConcept C2778496887 @default.
• W2809920244 hasConcept C2778975655 @default.
• W2809920244 hasConcept C2779134260 @default.
• W2809920244 hasConcept C2780132546 @default.
• W2809920244 hasConcept C2780564577 @default.
• W2809920244 hasConcept C2781059491 @default.
• W2809920244 hasConcept C2908647359 @default.
• W2809920244 hasConcept C71924100 @default.
• W2809920244 hasConcept C99454951 @default.
• W2809920244 hasConceptScore W2809920244C126322002 @default.
• W2809920244 hasConceptScore W2809920244C16005928 @default.
• W2809920244 hasConceptScore W2809920244C23131810 @default.
• W2809920244 hasConceptScore W2809920244C2776260265 @default.
• W2809920244 hasConceptScore W2809920244C2777138892 @default.
• W2809920244 hasConceptScore W2809920244C2777226972 @default.
• W2809920244 hasConceptScore W2809920244C2777575956 @default.
• W2809920244 hasConceptScore W2809920244C2778496887 @default.
• W2809920244 hasConceptScore W2809920244C2778975655 @default.
• W2809920244 hasConceptScore W2809920244C2779134260 @default.
• W2809920244 hasConceptScore W2809920244C2780132546 @default.
• W2809920244 hasConceptScore W2809920244C2780564577 @default.
• W2809920244 hasConceptScore W2809920244C2781059491 @default.
• W2809920244 hasConceptScore W2809920244C2908647359 @default.
• W2809920244 hasConceptScore W2809920244C71924100 @default.
• W2809920244 hasConceptScore W2809920244C99454951 @default.
• W2809920244 hasIssue "6" @default.
• W2809920244 hasLocation W28099202441 @default.
• W2809920244 hasLocation W28099202442 @default.
• W2809920244 hasOpenAccess W2809920244 @default.
• W2809920244 hasPrimaryLocation W28099202441 @default.
• W2809920244 hasRelatedWork W1491289496 @default.
• W2809920244 hasRelatedWork W1986925536 @default.
• W2809920244 hasRelatedWork W1992712177 @default.
• W2809920244 hasRelatedWork W2001428968 @default.
• W2809920244 hasRelatedWork W2140061052 @default.
• W2809920244 hasRelatedWork W2336343437 @default.
• W2809920244 hasRelatedWork W2564603710 @default.
• W2809920244 hasRelatedWork W2766755230 @default.
• W2809920244 hasRelatedWork W3215169261 @default.
• W2809920244 hasRelatedWork W71416396 @default.
• W2809920244 hasVolume "22" @default.
• W2809920244 isParatext "false" @default.
• W2809920244 isRetracted "false" @default.

• next